The UK-based biopharmaceutical company has two operating segments: the Platform segment, which generates the maximum revenue and consists of revenue-generating bioprocessing and process development activities undertaken for third parties, and the Product segment, which consists of the clinical and preclinical development of gene and cell therapy products. Oxford BioMedica's well-established lentiviral vector platform, LentiVector, is used to develop product candidates in-house before seeking partners to take the products into clinical trials. The company's US-based AAV manufacturing and innovation business, OXB Solutions, offers full scope process development and GMP operations using a commercially ready 'plug and play' platform, with a track record of successful IND regulatory filings and 45 500L GMP batches delivered in the last three years.